logo

Soleno Therapeutics Inc (SLNO)



Trade SLNO now with
  Date
  Headline
6/24/2020 9:38:17 AM Soleno Therapeutics Prices Public Offering Of 30.30 Mln Shares At $1.65/Shr
6/24/2020 8:39:28 AM Soleno Therapeutics Prices Public Offering Of 30.3 Mln Shares At $1.65/Shr
6/23/2020 4:04:35 PM Soleno Therapeutics Plans To Offer And Sell Shares Of Common Stock In Underwritten Public Offering
6/23/2020 4:03:17 PM Soleno Therapeutics Announces Proposed Public Offering Of Common Stock
1/6/2020 8:21:12 AM Soleno Therapeutics Completes Target Enrollment Of 100 Subjects In Ongoing Phase III Trial, DESTINY PWS
6/12/2019 8:09:13 AM Soleno Therapeutics Appoints Birgitte Volck To Its Board
5/13/2019 8:07:53 AM Soleno Therapeutics Q1 Net Loss $7.0 Mln Or $0.22/Shr Vs Loss $3.8 Mln Or $0.19/Shr Last Year
3/18/2019 8:11:35 AM Soleno Therapeutics Q4 Net Income $0.3 Mln Or $0.01/Shr Vs Loss $4.7 Mln Or $0.41/shr Last Year
10/8/2018 8:12:01 AM Soleno Therapeutics Says Poster Presentation On DCCR’s Safety Profile And Implications For PWS Phase III Study Design
10/1/2018 8:15:31 AM Soleno Therapeutics Presents Clinical Data On DCCR At Late-Breaking Session Of ESPE
9/17/2018 8:13:47 AM Soleno Therapeutics To Present DCCR Clinical Data At European Society For Paediatric Endocrinology
9/6/2018 8:11:01 AM Soleno Reports Expansion Of Ongoing Phase III Trial Of DCCR In Prader-Willi Syndrome To Include Younger Patients
9/6/2018 8:07:27 AM Soleno Therapeutics Announces Protocol Amendment To Its Ongoing Phase III Trial, DESTINY PWS
7/30/2018 8:07:33 AM Soleno Therapeutics Gets Fast Track Designation From FDA For DCCR For Prader-Willi Syndrome
5/16/2018 8:09:24 AM Soleno Therapeutics Reports Q1 Loss From Cont. Opns Of $3.2 Mln Or $0.17/shr